Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGDS | O60760 | 2/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | BRD4 | O60885 | 3/20 | 0.48 |
| ▸ | NAMPT | P43490 | 4/20 | 0.46 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19651836 | 0.87 | MAPK14 (0.53) | HPGDSKMT2ACYP2D6CYP2C9MAPK14 | |
| SCHEMBL19657229 | 0.85 | HPGDS (0.54) | HPGDSKMT2ACYP2D6CYP2C9BRD4 | |
| SCHEMBL19651825 | 0.85 | KMT2A (0.56) | KMT2ACYP2D6CYP2C9 | |
| SCHEMBL19651858 | 0.85 | CYP2D6 (0.57) | KMT2ACYP2D6CYP2C9MAPK14 | |
| SCHEMBL17758504 | 0.83 | HPGDS (0.52) | HPGDSKMT2ACYP2D6CYP2C9BRD4 | |
| SCHEMBL13175969 | 0.82 | HPGDS (0.53) | HPGDSKMT2ACYP2D6CYP2C9BRD4 | |
| SCHEMBL13175758 | 0.82 | HPGDS (0.53) | HPGDSKMT2ACYP2D6CYP2C9BRD4 | |
| SCHEMBL12825175 | 0.82 | HPGDS (0.53) | HPGDSKMT2ACYP2D6CYP2C9BRD4 | |
| SCHEMBL24923576 | 0.77 | KDM1A (0.50) | HPGDSBRD4NAMPTPOLB | |
| SCHEMBL14093944 | 0.77 | KMT2A (0.54) | HPGDSKMT2ABRD4MAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10183009-B2 | Therapeutic compounds and uses thereof | GENENTECH, INC. (US) | 2019-01-22 | — | — | US | disclosed |
| US-20170340605-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2017-11-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10183009-B2 | Therapeutic compounds and uses thereof | BRD4, BRDT, BRPF3 | HPGDS 2228/4885KMT2A 126/4885CYP2D6 3505/4885 |
| US-20170340605-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | BRD4, BRDT, BRPF3 | HPGDS 2228/4885KMT2A 126/4885CYP2D6 3505/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.